Top 10 pharmaceutical deal makers in 2010

10 December 2010

Big Pharma has had an active 2010, with a 20% increase in the number of deals concluded compared to last year according to latest figures released by MedTRACK, the biomedical database from Life Science Analytics. The “deals” include both licensing and merger and acquisition activities.

Sarah Terry, president of Life Science Analytics, comments: “The huge surge in deals concluded this year has been driven by: continued back filling of pipelines; a drive into new markets with a large number of deals including companies in emerging markets; and further diversification into generics and biologics.”

The Top 10 Dealmakers

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >